ASUS Blade AI Blood Analysis Software Gets HSA Approval in Singapore

ASUS Blade, an AI-powered blood film analysis software, has received Health Sciences Authority (HSA) approval as a Class B in vitro diagnostic (IVD) device in Singapore. The software demonstrated 99–100% agreement in key diagnostic metrics, indicating high accuracy in analyzing blood samples. This approval marks a significant regulatory milestone for ASUS in the healthcare AI sector, enabling deployment in Singaporean medical laboratories. The software is designed to assist pathologists by automating the analysis of blood films, potentially reducing diagnostic turnaround times and human error. ASUS has been expanding its healthcare AI portfolio, and this approval positions it to compete with established players like Siemens Healthineers and Roche in the digital pathology market.

Global Impact

Economically, this approval opens a new revenue stream for ASUS in the medical software market, which is projected to grow at 12% CAGR through 2030. Politically, it strengthens Singapore's position as a hub for AI-driven healthcare innovation, potentially attracting further investment.